8-K: MannKind Acquires scPharmaceuticals, Expands into Cardiorenal

MannKind Corporation will acquire scPharmaceuticals Inc. for up to $6.35 per share, diversifying its revenue and expanding into the cardiometabolic market with FUROSCIX.

Summary

• MannKind Corporation will acquire scPharmaceuticals Inc. through a tender offer for $5.35 per share in cash at closing, plus one non-tradeable Contingent Value Right (CVR) per share.
• The CVR represents the right to receive up to an aggregate of $1.00 in cash per CVR, based on achieving specific regulatory and net sales milestones.
• The total consideration is up to $6.35 per share, valuing the equity at approximately $303 million at closing and the total deal at up to approximately $360 million.
• This represents a 36% premium to scPharmaceuticals' 90-trading day VWAP and up to a 31% premium to its closing price on August 22, 2025.
• The acquisition is expected to close in the fourth quarter of 2025, subject to regulatory approvals and customary conditions.
• Principal stockholders, including John H. Tucker (CEO) and OrbiMed Advisors LLC affiliates, owning approximately 11.5% of outstanding shares, have agreed to tender their shares.
• MannKind secured an additional $175.0 million incremental delayed draw term loan from Blackstone to finance a portion of the transaction costs.
• Upon closing, MannKind will repay and extinguish scPharmaceuticals' outstanding debt and buy out revenue payment rights with Perceptive Credit Holdings IV, LP, estimated at $81.0 million.
• The FUROSCIX ReadyFlow Autoinjector is on track for a Q3 2025 sNDA submission, with potential FDA approval in Q3 2026.

Sentiment

Score: 8

Explanation: The acquisition of scPharmaceuticals and FUROSCIX is a highly strategic move for MannKind, diversifying its revenue base, expanding into a large and complementary market (cardiorenal medicine), and leveraging existing commercial infrastructure. The strong growth of FUROSCIX, coupled with the potential of the autoinjector and MannKind's pipeline, presents significant long-term value creation opportunities. The secured additional financing from Blackstone further strengthens MannKind's position.

Positives

• The acquisition diversifies MannKind's revenue base with three commercial assets (Afrezza, FUROSCIX, V-Go) and Tyvaso DPI-related revenues, projecting an annualized run rate over $370 million based on Q2 2025 results.
• MannKind expects to accelerate double-digit annual revenue growth with potential to expand market reach in the U.S. and globally.
• Strategic expansion into cardiorenal medicine establishes a new cardiometabolic business alongside MannKind's orphan lung division.
• FUROSCIX addresses a significant unmet medical need in fluid overload for chronic heart failure (CHF) and chronic kidney disease (CKD) patients, with an estimated total addressable market over $10 billion in the U.S. alone.
• scPharmaceuticals demonstrated strong commercial momentum with H1 2025 net sales of $27.8 million, up 96% year-over-year, driven by sales force expansion and growth in integrated delivery networks.
• The FUROSCIX ReadyFlow Autoinjector, targeting a Q3 2025 sNDA submission, could significantly reduce treatment time from five hours to less than 10 seconds, unlocking additional market opportunity with a formulation patent expiring in 2040.
• The deal leverages complementary business models and cultures, integrating scPharmaceuticals' cardiovascular expertise with MannKind's endocrinology strength to support FUROSCIX's CKD approval.
• MannKind plans to retain scPharmaceuticals' team to continue FUROSCIX's success in CHF.
• MannKind's late-stage pipeline, including Inhaled Clofazimine (MNKD-101) in Phase 3 for NTM lung disease and nintedanib DPI (MNKD-201) expected to initiate Phase 2 for IPF by year-end 2025, continues to progress.
• The additional $175 million funding from Blackstone ensures sufficient capital to support the acquisition and strategic objectives.

Risks

• MannKind's ability to complete the transaction on the proposed terms and schedule, or at all, is uncertain.
• There is a risk that various conditions to the transaction, such as scPharmaceuticals stockholders tendering sufficient shares, may not be satisfied or waived.
• The merger agreement could be terminated due to various events, changes, or circumstances.
• MannKind's ability to meet the conditions for drawing down the additional funding from the Blackstone credit facility is a risk.
• Legal proceedings may be instituted against MannKind, scPharmaceuticals, or others relating to the transaction, potentially resulting in significant costs of defense, indemnification, and liability.
• Failure or delay in receiving required regulatory approvals for the transaction could impact closing.
• The possibility of competing offers for scPharmaceuticals exists.
• The proposed transaction may cause disruption, making it more difficult to conduct business as usual or maintain relationships with customers, employees, or suppliers.
• There is a risk that MannKind may not be able to retain scPharmaceuticals' employees following the closing, given the at-will nature of their employment.
• Acquisitions carry inherent risks, such as difficulties in successful business integration, higher-than-expected integration costs or time, or the failure of expected benefits to materialize.
• Risks associated with developing product candidates include unforeseen delays that may impact the timing of clinical trials and reporting data.
• Uncertainty exists regarding the expected financial performance of scPharmaceuticals and its products and product candidates.
• There is no assurance that the CVR milestone payments will ever be achieved or that any milestone payment will be made.
• If scPharmaceuticals does not achieve the perceived benefits of the proposed transaction as rapidly or to the extent anticipated by financial analysts or investors, the market price of MannKind's shares could decline.

Future Outlook

MannKind anticipates diversifying and accelerating its double-digit revenue growth over the next decade, driven by multiple anticipated product launches and indication expansions. Key growth drivers include an Afrezza adult label update, India launch, and pediatric sBLA submission; the FUROSCIX Autoinjector sNDA submission in Q3 2025; upcoming data readouts from TETON 1 and 2 studies for Tyvaso in IPF; and the initiation of a Phase 2 clinical trial for nintedanib DPI (MNKD-201) by year-end 2025. The company expects to strengthen its position as a patient-centric leader in cardiometabolic and lung diseases.

Management Comments

• Michael Castagna, CEO of MannKind Corporation, stated: 'This acquisition expands our patient-centered brands and highlights MannKind’s dedication to delivering innovative therapies for cardiometabolic and orphan lung diseases. With multiple anticipated product launches and indication expansions, we expect to continue to diversify our revenue streams and accelerate our double-digit growth goals over the next decade.'
• John Tucker, CEO of scPharmaceuticals, commented: 'By combining our innovative products with MannKind’s proven commercial capabilities and shared commitment to advancing patient care, we believe MannKind can accelerate access to important therapies and create meaningful value for patients, providers, and stockholders.'

Industry Context

This acquisition marks MannKind's strategic entry into the cardiorenal medicine market, establishing a new cardiometabolic business alongside its existing orphan lung division. This move aligns with a broader industry trend of pharmaceutical companies seeking to diversify their therapeutic portfolios and leverage existing commercial infrastructures for new high-growth assets. FUROSCIX addresses a significant unmet need in fluid overload for chronic heart failure and chronic kidney disease patients, a market segment with substantial growth potential. The focus on an autoinjector delivery system for FUROSCIX also reflects the industry's push towards more convenient, patient-centric drug administration, potentially reducing hospitalizations and improving patient outcomes.

Comparison to Industry Standards

• FUROSCIX, delivering furosemide, is positioned as utilizing the 'gold standard' hospital diuretic, suggesting a strong efficacy profile comparable to established treatments.
• The estimated total addressable market for FUROSCIX of over $10 billion in the U.S. alone indicates a substantial market opportunity, potentially outperforming many niche pharmaceutical products.
• scPharmaceuticals' H1 2025 net sales growth of 96% year-over-year demonstrates exceptional commercial momentum, which is significantly higher than typical growth rates for established pharmaceutical products and suggests strong market adoption.
• The premium paid for scPharmaceuticals (36% to 90-day VWAP, up to 31% to recent closing) is within the range often seen in strategic pharmaceutical acquisitions, particularly for companies with innovative products and significant growth potential.

Corporate Governance

Related Party Transactions

• John H. Tucker, scPharmaceuticals' President and Chief Executive Officer, and entities affiliated with OrbiMed Advisors LLC, as Principal Stockholders, entered into Tender and Support Agreements with MannKind and Purchaser. They agreed to tender their approximately 11.5% of outstanding Target Shares in the Offer and vote in support of the transactions.

Stakeholder Impact

• Shareholders of scPharmaceuticals will receive $5.35 per share in cash plus a CVR potentially worth up to $1.00, representing a significant premium and potential future upside.
• Shareholders of MannKind are expected to benefit from revenue diversification, accelerated growth, and expansion into a new, large market segment.
• Employees of scPharmaceuticals will be integrated into MannKind, with MannKind expecting to retain the talented team to continue FUROSCIX's success.
• Customers and providers will potentially gain accelerated access to important therapies, particularly with the development of the FUROSCIX autoinjector, which could offer more convenient treatment options.
• Creditors of scPharmaceuticals (Perceptive Credit Holdings IV, LP) will have their outstanding indebtedness repaid and revenue payment rights bought out, estimated at $81.0 million, upon closing.

Next Steps

• MannKind will promptly commence a tender offer to acquire all outstanding shares of scPharmaceuticals common stock.
• The FUROSCIX ReadyFlow Autoinjector is on track for a Q3 2025 supplemental New Drug Application (sNDA) submission.
• The transaction is expected to close in the fourth quarter of 2025, subject to regulatory approvals and customary conditions.
• Upon closing, MannKind will repay and extinguish scPharmaceuticals' outstanding indebtedness and buy out revenue payment rights with Perceptive Credit Holdings IV, LP.
• MannKind expects to continue FUROSCIX's ongoing success in heart failure with the scPharmaceuticals team.
• MannKind's nintedanib DPI (MNKD-201) is expected to initiate a Phase 2 clinical trial for IPF by year-end 2025.
• MannKind will host a conference call on August 25, 2025, at 8:30 a.m. ET to discuss the transaction.

Key Dates

Recommendation

This acquisition significantly enhances MannKind's commercial portfolio and strategic positioning in the cardiometabolic and orphan lung disease markets. FUROSCIX addresses a large unmet medical need with strong existing sales momentum and substantial future growth potential, particularly with the upcoming autoinjector sNDA. The deal structure, including CVRs, aligns incentives for future performance. The secured financing from Blackstone demonstrates strong institutional support. This move is expected to accelerate MannKind's double-digit revenue growth goals and create meaningful long-term value for shareholders.

Keywords

MannKind, scPharmaceuticals, Acquisition, Merger, FUROSCIX, Cardiometabolic, Orphan Lung Disease, CHF, CKD, Autoinjector, FDA Approval, CVR, Contingent Value Right, Biopharma, Pharmaceuticals, Healthcare, Blackstone Financing, Drug Delivery, MNKD, SCPH